During this disruption, the accuracy of diagnosis becomes even more important, so that vital care is delivered promptly while unnecessary visits are avoided. Department leaders are addressing the large and growing backlog and prioritizing patients in a manner that balances the risk of cancer to patients and the risk of Covid-19 to both patients and healthcare providers.
Koios DS BreastTM uses patented machine learning algorithms to assist physicians analyzing breast ultrasound lesions found during routine mammograms or self-exams. Ultrasound scans are typically required for added clarity in women with dense breast tissue where traditional mammogram technology is unable to detect most cancerous tissue. An ultrasound exam is part of the diagnostic pathway whenever a mammogram uncovers something suspicious. Historically the challenge with ultrasound technology has been the manual nature of each exam making it highly variable, and interpretation is plagued by a high percentage of false positive findings yet over 130,000 missed cancers (or false negatives) occur each year in just the United States alone.
Ad Statistics
Times Displayed: 50459
Times Visited: 1437 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The decision support software was recently the focus of the largest, most comprehensive reader study of AI decision support analyzing ultrasound images of breast lesions. Fifteen physicians each interpreted 900 cases twice in random order. The AI system improved physician sensitivity and/or specificity for 100% of the participating physicians and for 93%, both.
Key findings of the peer-reviewed report indicated up to 6 additional malignancies were found per 100 cancers presented with a simultaneous reduction in benign biopsies of 31%, reduced BI-RADS 3 follow-up recommendations, and improved consistency of interpretation, both inter- and intra-operator. As of June 2020, over 30,000 patient cases have been analyzed using the Koios AI system with several prominent institutions and community-based health systems are expected to be activating the software in Q3.
About Koios Medical, Inc: Koios DSTM Breast is the only FDA-cleared cancer diagnosis software using AI on breast ultrasound images. Koios DS works as an expert on-demand second opinion for classifying suspicious lesions and aligning to a BI-RADS rating, while prepopulating diagnostic reports. AI algorithms are trained on nearly 500,000 ultrasound images. Software integrates into all major PACS workstation viewers and is also available on select scanners. Learn more at www.koiosmedical.com.
Back to HCB News
